Mayumi Mochizuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mayumi Mochizuki has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Eiji Aramaki
Nara Institute of Science and Technology, Ikoma, Japan
5 shared publications - Haruki Ishikawa
Department of Pharmacy, Keio University Hospital, Tokyo, Japan
4 shared publications - Minae Isawa
Faculty of Pharmacy, Keio University, Tokyo, Japan
4 shared publications - Riri Kato
Faculty of Pharmacy, Keio University, Tokyo, Japan
4 shared publications - Tohru Aomori
Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Japan
4 shared publications - Tomohiro Nishiyama
Nara Institute of Science and Technology, Ikoma-shi, Japan
4 shared publications
Latest Publications
- Open Access
- 4 March 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13, e68863
Performance Improvement of a Natural Language Processing Tool for Extracting Patient Narratives Related to Medical States From Japanese Pharmaceutical Care Records by Increasing the Amount of Training Data: Natural Language Processing Analysis and Validation Study
Background: Patients’ oral expressions serve as valuable sources of clinical information to improve pharmacotherapy. Natural language processing (NLP) is a useful approach for analyzing unstructured text data, such as patient narratives. However, few studies have focused on using NLP for narratives in the Japanese language. Objective: We aimed to develop a high-performance NLP system for extracting clinical information from patient narratives by examining the performance progression with a gradual increase in the amount of training data. Methods: We used subjective texts from the pharmaceutical care records of Keio University Hospital from April 1, 2018, to March 31, 2019, comprising 12,004 records from 6559 cases. After preprocessing, we annotated diseases and symptoms within the texts. We then trained and evaluated a deep learning model (bidirectional encoder representations from transformers combined with a conditional random field [BERT-CRF]) through 10-fold cross-validation. The annotated data were divided into 10 subsets, and the amount of training data was progressively increased over 10 steps. We also analyzed the causes of errors. Finally, we applied the developed system to the analysis of case report texts to evaluate its usability for texts from other sources. Results: The F1-score of the system improved from 0.67 to 0.82 as the amount of training data increased from 1200 to 12,004 records. The F1-score reached 0.78 with 3600 records and was largely similar thereafter. As performance improved, errors from incorrect extractions decreased significantly, which resulted in an increase in precision. For case reports, the F1-score also increased from 0.34 to 0.41 as the training dataset expanded from 1200 to 12,004 records. Performance was lower for extracting symptoms from case report texts compared with pharmaceutical care records, suggesting that this system is more specialized for analyzing subjective data from pharmaceutical care records. Conclusions: We successfully developed a high-performance system specialized in analyzing subjective data from pharmaceutical care records by training a large dataset, with near-complete saturation of system performance with about 3600 training records. This system will be useful for monitoring symptoms, offering benefits for both clinical practice and research.
- 4 March 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13, e68863
Open AccessPerformance Improvement of a Natural Language Processing Tool for Extracting Patient Narratives Related to Medical States From Japanese Pharmaceutical Care Records by Increasing the Amount of Training Data: Natural Language Processing Analysis and Validation Study
Background: Patients’ oral expressions serve as valuable sources of clinical information to improve pharmacotherapy. Natural language processing (NLP) is a useful approach for analyzing unstructured text data, such as patient narratives. However, few studies have focused on using NLP for narratives in the Japanese language. Objective: We aimed to develop a high-performance NLP system for extracting clinical information from patient narratives by examining the performance progression with a gradual increase in the amount of training data. Methods: We used subjective texts from the pharmaceutical care records of Keio University Hospital from April 1, 2018, to March 31, 2019, comprising 12,004 records from 6559 cases. After preprocessing, we annotated diseases and symptoms within the texts. We then trained and evaluated a deep learning model (bidirectional encoder representations from transformers combined with a conditional random field [BERT-CRF]) through 10-fold cross-validation. The annotated data were divided into 10 subsets, and the amount of training data was progressively increased over 10 steps. We also analyzed the causes of errors. Finally, we applied the developed system to the analysis of case report texts to evaluate its usability for texts from other sources. Results: The F1-score of the system improved from 0.67 to 0.82 as the amount of training data increased from 1200 to 12,004 records. The F1-score reached 0.78 with 3600 records and was largely similar thereafter. As performance improved, errors from incorrect extractions decreased significantly, which resulted in an increase in precision. For case reports, the F1-score also increased from 0.34 to 0.41 as the training dataset expanded from 1200 to 12,004 records. Performance was lower for extracting symptoms from case report texts compared with pharmaceutical care records, suggesting that this system is more specialized for analyzing subjective data from pharmaceutical care records. Conclusions: We successfully developed a high-performance system specialized in analyzing subjective data from pharmaceutical care records by training a large dataset, with near-complete saturation of system performance with about 3600 training records. This system will be useful for monitoring symptoms, offering benefits for both clinical practice and research.
- Open Access
- 25 November 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Performance Improvement of the Natural Language Processing Tool to Extract Patient Narratives Related to Medical States From Japanese Pharmaceutical Care Records: Effects of an Increase in the Amount of Training Data (Preprint)
BACKGROUND To improve pharmacotherapy, patients’ oral expressions serve as valuable sources of clinical information. Natural language processing (NLP) is a useful approach for analyzing unstructured text data, such as patient narratives. However, few studies have focused on using NLP for narratives in the Japanese language. OBJECTIVE To develop a high-performance NLP system for extracting clinical information from patient narratives, we examined the performance progression as the amount of training data was gradually increased. METHODS Subjective texts from the pharmaceutical care records of Keio University Hospital from April 1, 2018 to March 31, 2019, comprising 12,004 records from 6,559 cases, were used. After preprocessing, we annotated diseases and symptoms within the texts. We then trained and evaluated deep learning models—bidirectional encoder representations from transformers combined with a conditional random field (BERT-CRF)—by 10-fold cross-validation. The annotated data were divided into 10 subsets, and the amount of training data was progressively increased over 10 steps. We also analyzed the causes of errors. Finally, we applied the developed system to the analysis of case report texts to evaluate its usability for texts from other sources. RESULTS The F1-score of the system improved from 0.67 to 0.82 as the amount of training data increased from 1,200 to 12,004 records. The F1-score reached 0.78 with 3,600 records and largely saturated thereafter. As performance improved, errors from incorrect extractions decreased significantly, increasing precision. For case reports, the F1-score also increased from 0.34 to 0.41 as the training dataset expanded from 1,200 to 12,004 records. Performance was lower for extracting symptoms from case report texts compared with pharmaceutical care records, suggesting that this system is more specialized for analyzing subjective data from pharmaceutical care records. CONCLUSIONS We successfully developed a high-performance system specialized in analyzing subjective data from pharmaceutical care records by training a large dataset, with near-complete saturation of system performance with about 3,600 training records. This system will be useful for monitoring symptoms, offering benefits for both clinical practice and research.
- 25 November 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessPerformance Improvement of the Natural Language Processing Tool to Extract Patient Narratives Related to Medical States From Japanese Pharmaceutical Care Records: Effects of an Increase in the Amount of Training Data (Preprint)
BACKGROUND To improve pharmacotherapy, patients’ oral expressions serve as valuable sources of clinical information. Natural language processing (NLP) is a useful approach for analyzing unstructured text data, such as patient narratives. However, few studies have focused on using NLP for narratives in the Japanese language. OBJECTIVE To develop a high-performance NLP system for extracting clinical information from patient narratives, we examined the performance progression as the amount of training data was gradually increased. METHODS Subjective texts from the pharmaceutical care records of Keio University Hospital from April 1, 2018 to March 31, 2019, comprising 12,004 records from 6,559 cases, were used. After preprocessing, we annotated diseases and symptoms within the texts. We then trained and evaluated deep learning models—bidirectional encoder representations from transformers combined with a conditional random field (BERT-CRF)—by 10-fold cross-validation. The annotated data were divided into 10 subsets, and the amount of training data was progressively increased over 10 steps. We also analyzed the causes of errors. Finally, we applied the developed system to the analysis of case report texts to evaluate its usability for texts from other sources. RESULTS The F1-score of the system improved from 0.67 to 0.82 as the amount of training data increased from 1,200 to 12,004 records. The F1-score reached 0.78 with 3,600 records and largely saturated thereafter. As performance improved, errors from incorrect extractions decreased significantly, increasing precision. For case reports, the F1-score also increased from 0.34 to 0.41 as the training dataset expanded from 1,200 to 12,004 records. Performance was lower for extracting symptoms from case report texts compared with pharmaceutical care records, suggesting that this system is more specialized for analyzing subjective data from pharmaceutical care records. CONCLUSIONS We successfully developed a high-performance system specialized in analyzing subjective data from pharmaceutical care records by training a large dataset, with near-complete saturation of system performance with about 3,600 training records. This system will be useful for monitoring symptoms, offering benefits for both clinical practice and research.
- Open Access
- 4 June 2024
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 8 (1) , e55798
Using the Natural Language Processing System Medical Named Entity Recognition-Japanese to Analyze Pharmaceutical Care Records: Natural Language Processing Analysis
Background: Large language models have propelled recent advances in artificial intelligence technology, facilitating the extraction of medical information from unstructured data such as medical records. Although named entity recognition (NER) is used to extract data from physicians’ records, it has yet to be widely applied to pharmaceutical care records. Objective: In this study, we aimed to investigate the feasibility of automatic extraction of the information regarding patients’ diseases and symptoms from pharmaceutical care records. The verification was performed using Medical Named Entity Recognition-Japanese (MedNER-J), a Japanese disease-extraction system designed for physicians’ records. Methods: MedNER-J was applied to subjective, objective, assessment, and plan data from the care records of 49 patients who received cefazolin sodium injection at Keio University Hospital between April 2018 and March 2019. The performance of MedNER-J was evaluated in terms of precision, recall, and F1-score. Results: The F1-scores of NER for subjective, objective, assessment, and plan data were 0.46, 0.70, 0.76, and 0.35, respectively. In NER and positive-negative classification, the F1-scores were 0.28, 0.39, 0.64, and 0.077, respectively. The F1-scores of NER for objective (0.70) and assessment data (0.76) were higher than those for subjective and plan data, which supported the superiority of NER performance for objective and assessment data. This might be because objective and assessment data contained many technical terms, similar to the training data for MedNER-J. Meanwhile, the F1-score of NER and positive-negative classification was high for assessment data alone (F1-score=0.64), which was attributed to the similarity of its description format and contents to those of the training data. Conclusions: MedNER-J successfully read pharmaceutical care records and showed the best performance for assessment data. However, challenges remain in analyzing records other than assessment data. Therefore, it will be necessary to reinforce the training data for subjective data in order to apply the system to pharmaceutical care records.
- 4 June 2024
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 8 (1) , e55798
Open AccessUsing the Natural Language Processing System Medical Named Entity Recognition-Japanese to Analyze Pharmaceutical Care Records: Natural Language Processing Analysis
Background: Large language models have propelled recent advances in artificial intelligence technology, facilitating the extraction of medical information from unstructured data such as medical records. Although named entity recognition (NER) is used to extract data from physicians’ records, it has yet to be widely applied to pharmaceutical care records. Objective: In this study, we aimed to investigate the feasibility of automatic extraction of the information regarding patients’ diseases and symptoms from pharmaceutical care records. The verification was performed using Medical Named Entity Recognition-Japanese (MedNER-J), a Japanese disease-extraction system designed for physicians’ records. Methods: MedNER-J was applied to subjective, objective, assessment, and plan data from the care records of 49 patients who received cefazolin sodium injection at Keio University Hospital between April 2018 and March 2019. The performance of MedNER-J was evaluated in terms of precision, recall, and F1-score. Results: The F1-scores of NER for subjective, objective, assessment, and plan data were 0.46, 0.70, 0.76, and 0.35, respectively. In NER and positive-negative classification, the F1-scores were 0.28, 0.39, 0.64, and 0.077, respectively. The F1-scores of NER for objective (0.70) and assessment data (0.76) were higher than those for subjective and plan data, which supported the superiority of NER performance for objective and assessment data. This might be because objective and assessment data contained many technical terms, similar to the training data for MedNER-J. Meanwhile, the F1-score of NER and positive-negative classification was high for assessment data alone (F1-score=0.64), which was attributed to the similarity of its description format and contents to those of the training data. Conclusions: MedNER-J successfully read pharmaceutical care records and showed the best performance for assessment data. However, challenges remain in analyzing records other than assessment data. Therefore, it will be necessary to reinforce the training data for subjective data in order to apply the system to pharmaceutical care records.
- Open Access
- 26 December 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Using the Natural Language Processing System Medical Named Entity Recognition-Japanese to Analyze Pharmaceutical Care Records: Natural Language Processing Analysis (Preprint)
BACKGROUND Large language models have propelled recent advances in artificial intelligence technology, facilitating the extraction of medical information from unstructured data such as medical records. Although named entity recognition (NER) is used to extract data from physicians’ records, it has yet to be widely applied to pharmaceutical care records. OBJECTIVE In this study, we aimed to investigate the feasibility of automatic extraction of the information regarding patients’ diseases and symptoms from pharmaceutical care records. The verification was performed using Medical Named Entity Recognition-Japanese (MedNER-J), a Japanese disease-extraction system designed for physicians’ records. METHODS MedNER-J was applied to subjective, objective, assessment, and plan data from the care records of 49 patients who received cefazolin sodium injection at Keio University Hospital between April 2018 and March 2019. The performance of MedNER-J was evaluated in terms of precision, recall, and F1-score. RESULTS The F1-scores of NER for subjective, objective, assessment, and plan data were 0.46, 0.70, 0.76, and 0.35, respectively. In NER and positive-negative classification, the F1-scores were 0.28, 0.39, 0.64, and 0.077, respectively. The F1-scores of NER for objective (0.70) and assessment data (0.76) were higher than those for subjective and plan data, which supported the superiority of NER performance for objective and assessment data. This might be because objective and assessment data contained many technical terms, similar to the training data for MedNER-J. Meanwhile, the F1-score of NER and positive-negative classification was high for assessment data alone (F1-score=0.64), which was attributed to the similarity of its description format and contents to those of the training data. CONCLUSIONS MedNER-J successfully read pharmaceutical care records and showed the best performance for assessment data. However, challenges remain in analyzing records other than assessment data. Therefore, it will be necessary to reinforce the training data for subjective data in order to apply the system to pharmaceutical care records.
- 26 December 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessUsing the Natural Language Processing System Medical Named Entity Recognition-Japanese to Analyze Pharmaceutical Care Records: Natural Language Processing Analysis (Preprint)
BACKGROUND Large language models have propelled recent advances in artificial intelligence technology, facilitating the extraction of medical information from unstructured data such as medical records. Although named entity recognition (NER) is used to extract data from physicians’ records, it has yet to be widely applied to pharmaceutical care records. OBJECTIVE In this study, we aimed to investigate the feasibility of automatic extraction of the information regarding patients’ diseases and symptoms from pharmaceutical care records. The verification was performed using Medical Named Entity Recognition-Japanese (MedNER-J), a Japanese disease-extraction system designed for physicians’ records. METHODS MedNER-J was applied to subjective, objective, assessment, and plan data from the care records of 49 patients who received cefazolin sodium injection at Keio University Hospital between April 2018 and March 2019. The performance of MedNER-J was evaluated in terms of precision, recall, and F1-score. RESULTS The F1-scores of NER for subjective, objective, assessment, and plan data were 0.46, 0.70, 0.76, and 0.35, respectively. In NER and positive-negative classification, the F1-scores were 0.28, 0.39, 0.64, and 0.077, respectively. The F1-scores of NER for objective (0.70) and assessment data (0.76) were higher than those for subjective and plan data, which supported the superiority of NER performance for objective and assessment data. This might be because objective and assessment data contained many technical terms, similar to the training data for MedNER-J. Meanwhile, the F1-score of NER and positive-negative classification was high for assessment data alone (F1-score=0.64), which was attributed to the similarity of its description format and contents to those of the training data. CONCLUSIONS MedNER-J successfully read pharmaceutical care records and showed the best performance for assessment data. However, challenges remain in analyzing records other than assessment data. Therefore, it will be necessary to reinforce the training data for subjective data in order to apply the system to pharmaceutical care records.
- Open Access
- 10 May 2019
- Published by Japanese Society of Pharmaceutical Health Care and Sciences in Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
- Vol. 45 (5) , 285-291
Effects of Co-administration of Proton Pump Inhibitors on Methotrexate Elimination and Adverse Events
Co-administration of methotrexate (MTX) and proton pump inhibitors (PPIs) is reported to increase serum MTX concentrations in patients receiving high-dose MTX therapy. However, the range of MTX high dosage is wide. We attempted to clarify the effects of PPIs co-administration on the elimination of MTX at the fixed dose of 1 g/m2 in a retrospective cohort study of 46 patients with hematological malignancies who underwent a total of 91 cycles of chemotherapy. Data on gender, age, concomitant drugs, and laboratory test results were analyzed. The median and first to third quartile of MTX concentrations with and without PPI co-administration at 24, 48, and 72 h postdosing were 17.42 (14.75 - 22.34) vs 19.96 (14.97 - 23.10) (P = 0.627), 0.25 (0.15 - 0.42) vs 0.34 (0.17 - 0.96) (P = 0.159), and 0.06 (0.04 - 0.10) vs 0.07 (0.04 - 0.23) (P = 0.357), respectively. No statistically significant differences were observed in the number of patients with delayed MTX elimination with each PPI. Nausea (all grades) was significantly less frequent in patients receiving PPIs (38% with vs 68% without, P < 0.05). Multivariate analysis results indicated that differences in creatinine clearance (24 h after MTX administration and baseline) (OR, 0.92; 95%CI, 0.88 - 0.97), gender (OR, 4.95; 95%CI, 1.55 - 15.81), and age (OR, 1.04; 95%CI, 1.00 - 1.08) were risk factors for delayed MTX elimination. These findings suggest that PPI co-administration does not affect MTX elimination at the dose of 1 g/m2, but could relief nausea associated with chemotherapy.
- 10 May 2019
- Published by Japanese Society of Pharmaceutical Health Care and Sciences in Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
- Vol. 45 (5) , 285-291
Open AccessEffects of Co-administration of Proton Pump Inhibitors on Methotrexate Elimination and Adverse Events
Co-administration of methotrexate (MTX) and proton pump inhibitors (PPIs) is reported to increase serum MTX concentrations in patients receiving high-dose MTX therapy. However, the range of MTX high dosage is wide. We attempted to clarify the effects of PPIs co-administration on the elimination of MTX at the fixed dose of 1 g/m2 in a retrospective cohort study of 46 patients with hematological malignancies who underwent a total of 91 cycles of chemotherapy. Data on gender, age, concomitant drugs, and laboratory test results were analyzed. The median and first to third quartile of MTX concentrations with and without PPI co-administration at 24, 48, and 72 h postdosing were 17.42 (14.75 - 22.34) vs 19.96 (14.97 - 23.10) (P = 0.627), 0.25 (0.15 - 0.42) vs 0.34 (0.17 - 0.96) (P = 0.159), and 0.06 (0.04 - 0.10) vs 0.07 (0.04 - 0.23) (P = 0.357), respectively. No statistically significant differences were observed in the number of patients with delayed MTX elimination with each PPI. Nausea (all grades) was significantly less frequent in patients receiving PPIs (38% with vs 68% without, P < 0.05). Multivariate analysis results indicated that differences in creatinine clearance (24 h after MTX administration and baseline) (OR, 0.92; 95%CI, 0.88 - 0.97), gender (OR, 4.95; 95%CI, 1.55 - 15.81), and age (OR, 1.04; 95%CI, 1.00 - 1.08) were risk factors for delayed MTX elimination. These findings suggest that PPI co-administration does not affect MTX elimination at the dose of 1 g/m2, but could relief nausea associated with chemotherapy.
- Open Access
- 27 September 2018
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 6 (3) , e11021
Extraction and Standardization of Patient Complaints from Electronic Medication Histories for Pharmacovigilance: Natural Language Processing Analysis in Japanese
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Although methods of obtaining knowledge from texts written by healthcare professionals such as electronic medical records and discharge summaries have been studied, there are few reports analyzing free-text data on patients’ complaints in Japanese. Objective: This study aimed to establish a new method for extracting keywords from patients’ free descriptions accumulated in Japanese medical institutions. Methods: We developed a system that automatically annotates free-text data with the codes of the Tenth Revision of the International Statistical Classification of Diseases and Related Health Problems (ICD10) using electronic medication history data (target period: September 1, 2015 to August 31, 2016). The performance of the system was evaluated through comparisons with data manually annotated by healthcare workers. Results: The number of ICD10 codes extracted from 5,000 patient statements by healthcare workers was 2,348, while the system extracted 2,236 codes. Of those cases, 1,480 matched. Compared with manual extraction, the performance of the system was 0.66 in terms of precision, 0.63 in recall, and 0.65 for the F-measure. Conclusions: Our results suggested that the system was helpful for extracting and standardizing patient’s words related to symptoms from massive amounts of free-text data instead of manual work. After improving the extraction accuracy, we expect to utilize this system to detect the signals of adverse drug reactions from patients’ statements in the future.
- 27 September 2018
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 6 (3) , e11021
Open AccessExtraction and Standardization of Patient Complaints from Electronic Medication Histories for Pharmacovigilance: Natural Language Processing Analysis in Japanese
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Although methods of obtaining knowledge from texts written by healthcare professionals such as electronic medical records and discharge summaries have been studied, there are few reports analyzing free-text data on patients’ complaints in Japanese. Objective: This study aimed to establish a new method for extracting keywords from patients’ free descriptions accumulated in Japanese medical institutions. Methods: We developed a system that automatically annotates free-text data with the codes of the Tenth Revision of the International Statistical Classification of Diseases and Related Health Problems (ICD10) using electronic medication history data (target period: September 1, 2015 to August 31, 2016). The performance of the system was evaluated through comparisons with data manually annotated by healthcare workers. Results: The number of ICD10 codes extracted from 5,000 patient statements by healthcare workers was 2,348, while the system extracted 2,236 codes. Of those cases, 1,480 matched. Compared with manual extraction, the performance of the system was 0.66 in terms of precision, 0.63 in recall, and 0.65 for the F-measure. Conclusions: Our results suggested that the system was helpful for extracting and standardizing patient’s words related to symptoms from massive amounts of free-text data instead of manual work. After improving the extraction accuracy, we expect to utilize this system to detect the signals of adverse drug reactions from patients’ statements in the future.
- 1 July 2018
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 56 (07) , 310-320
Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan
To investigate quantitatively the risk factors for rhabdomyolysis or related symptoms associated with HMG-CoA reductase inhibitors (statins), we used the lipid-lowering drug database (32,157 patients) developed by the RAD-AR Council, Japan, based on the postmarketing surveillance (PMS) data of pharmaceutical companies to perform a nested case-control study. Of 26,849 patients taking statins, the case group was composed of 51 patients who experienced rhabdomyolysis or related symptoms while taking statins, and the control group was 1,020 patients randomly selected from patients who did not experience rhabdomyolysis or related symptoms while taking statins. Relevant factors that can be extracted from the database were: sex, age, body mass index (BMI), statin use duration, complications, concomitant medication, and clinical laboratory test values. Among those taking statins, 51 experienced rhabdomyolysis or related symptoms. Factors differing significantly between the two groups by univariate analysis were age, duration of statin intake, combination drugs (Ca antagonists, angiotensin II receptor blocker (ARB), cardiac drugs, benzodiazepines, mucoprotective drugs, insulin, α-glucosidase inhibitors), clinical laboratory results (high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase, alkaline phosphatase, total bilirubin), and complications (alcoholic hepatitis). Conditional multivariate logistic analysis of these factors yielded adjusted/odds ratios of 8.82 for the concomitant administration of an ARB and 3.45 for increased AST and 3.20 for increased total bilirubin levels. Risk factors for rhabdomyolysis or related symptoms associated with taking statins were combination with ARB and increases in AST or total bilirubin levels. .
- 1 July 2018
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 56 (07) , 310-320
Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan
To investigate quantitatively the risk factors for rhabdomyolysis or related symptoms associated with HMG-CoA reductase inhibitors (statins), we used the lipid-lowering drug database (32,157 patients) developed by the RAD-AR Council, Japan, based on the postmarketing surveillance (PMS) data of pharmaceutical companies to perform a nested case-control study. Of 26,849 patients taking statins, the case group was composed of 51 patients who experienced rhabdomyolysis or related symptoms while taking statins, and the control group was 1,020 patients randomly selected from patients who did not experience rhabdomyolysis or related symptoms while taking statins. Relevant factors that can be extracted from the database were: sex, age, body mass index (BMI), statin use duration, complications, concomitant medication, and clinical laboratory test values. Among those taking statins, 51 experienced rhabdomyolysis or related symptoms. Factors differing significantly between the two groups by univariate analysis were age, duration of statin intake, combination drugs (Ca antagonists, angiotensin II receptor blocker (ARB), cardiac drugs, benzodiazepines, mucoprotective drugs, insulin, α-glucosidase inhibitors), clinical laboratory results (high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase, alkaline phosphatase, total bilirubin), and complications (alcoholic hepatitis). Conditional multivariate logistic analysis of these factors yielded adjusted/odds ratios of 8.82 for the concomitant administration of an ARB and 3.45 for increased AST and 3.20 for increased total bilirubin levels. Risk factors for rhabdomyolysis or related symptoms associated with taking statins were combination with ARB and increases in AST or total bilirubin levels. .